Atherogenic index of plasma and risk of cardiovascular disease among Cameroonian postmenopausal women by unknown
RESEARCH Open Access
Atherogenic index of plasma and risk of
cardiovascular disease among Cameroonian
postmenopausal women
Jobert Richie N. Nansseu1,2*, Vicky Jocelyne Ama Moor3,4,5, Murielle Elsa D. Nouaga3, Bertrand Zing-Awona1,6,7,
Gladys Tchanana3 and Arthur Ketcha3
Abstract
Background : The paucity of data regarding the relationship between atherogenic index of plasma (AIP) and risk of
cardiovascular disease (CVD) in postmenopausal women living in sub-Saharan Africa prompted us to conduct this
study which aimed at assessing the interplay between AIP and risk of CVD among Cameroonian postmenopausal
women.
Methods: This was a cross-sectional study conducted among 108 postmenopausal women in Yaoundé, Cameroon.
Risk of CVD was calculated using the Framingham risk score, (FRS), and the AIP was derived as log (triglycerides/
high-density lipoproteins cholesterol).
Results: Mean age of participants equaled 56.4 ± 6.9 years. AIP values ranged from -0.40 to 0.85 with a mean of
0.21 ± 0.27. There was a positive and significant correlation between AIP and body mass index (r = 0.234; p = 0.015),
systolic blood pressure (r = 0.350; p < 0.001), diastolic blood pressure (r = 0.365; p < 0.001), fasting plasma glucose
(r = 0.314; p = 0.001), uric acid (r = 0.374; p < 0.001), and total cholesterol (r = 0.374; p < 0.001), but not with age
(r = -0.104; p = 0.284). The FRS varied between 1.2 % and >30 % with a mean of 13.4 ± 8.7 %. In univariable model,
AIP significantly influenced the risk of CVD (β = 11.94; p < 0.001; R2 = 0.136). But in the multivariable model, after
adjusting for confounders, AIP did not impact the risk of CVD anymore (adjusted β = 1.98; p = 0.487; R2 = 0.486).
Conclusion: AIP may not be an independent factor impacting the risk of CVD among Cameroonian
postmenopausal women. More studies are needed to better elucidate the interaction between AIP and risk
of CVD in our setting.
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Background
Menopause, which is the permanent cessation of men-
struation following loss of ovarian activity, has consider-
able impact on social, reproductive, physical and
psychological health of the woman [1]. While premeno-
pausal women have a lower incidence of cardiovascular
disease (CVD) compared with men of the same age, the
incidence of the disease in women increases dreadfully
after the age of 50 years [1]. The anti-atherogenic effect
of estrogens and the protection of females against CVD,
especially coronary heart disease are well described dur-
ing the premenopausal period [2]. Indeed, there is con-
vincing evidence that menopause is associated with a
pro-atherogenic lipid profile characterized by lower
high-density lipoproteins cholesterol (HDL-C), higher
low-density lipoproteins cholesterol (LDL-C) and trigly-
ceride (TG) levels [3], central adiposity [4], increased
diastolic blood pressure [5] and increased insulin resist-
ance [6], hence an increased likelihood to develop CVD.
A variety of indices have been used for the diagnosis
and prognosis of CVD. In this regard, some researchers
have looked at the relationship between TG and HDL-C,
and have shown for instance that the ratio of TG to
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HDL-C was a strong predictor of myocardial infarction
[7]. There have been some claims that the atherogenic
index of plasma (AIP), which is the logarithmic trans-
formation of the just-mentioned ratio (TG/HDL-C),
could be used as a significant predictor of atherosclerosis
[8], and CVD as well [9–11]. Dobiásová M suggested in-
deed that AIP values of -0.3 to 0.1 may be associated
with low, 0.1 to 0.24 with medium and above 0.24 with
high risk of CVD [10]. It was bolstered that the strong
correlation of AIP with lipoprotein particle size may ex-
plain its high predictive value of CVD occurrence [8].
However, there is paucity of data scrutinizing the
interplay between AIP and risk of CVD in postmeno-
pausal women living in Africa, especially south of the
Sahara. We therefore undertook the present study,
which aimed at investigating the link between AIP and
risk of CVD among Cameroonian postmenopausal
women.
Methods
Study design and participants
In January 2015, we conducted a cross-sectional study at
the Yaoundé University Teaching Hospital, Cameroon.
We recruited postmenopausal women whose last menses
dated back to at least 1 year, with no previous history of
cardiovascular events, in apparent good health, who
were visiting the study site for various reasons, and who
voluntarily accepted to take part in the survey. A con-
venient sample of 100 women was set, and women
fulfilling our inclusion criteria were enrolled during the
study period. Part of the methods is also reported
elsewhere [12].
Data collection
We used a structured pre-tested questionnaire for data
collection, including socio-demographic characteristics
(age, region of origin, profession, marital status), medical
history (past medical events, family history of diabetes,
hypertension or other relevant disease), and lifestyle
habits (physical exercise, smoking (defined as having
smoked any cigarettes in the past month), consumption
of alcohol, and consumption of fruits and vegetables).
Afterwards, a physical examination was undertaken dur-
ing which blood pressure (composite of systolic blood
pressure (SBP) and diastolic blood pressure (DBP) in
mmHg), body weight (to the nearest kilogram), and
height (to the nearest centimeter) were measured. Body
mass index (BMI) was subsequently derived as weight
(kg)/height × height (m). At the end of this stage, partici-
pants were given an appointment for blood collection.
Blood sampling and biochemical measurements
Fasting blood samples were collected after a 12-h overnight
fasting, and processed for biochemical determinations
including fasting plasma glucose (FPG), total choles-
terol (TC), triglycerides (TG), high-density lipopro-
teins cholesterol (HDL-C) and uric acid. Low-density
lipoproteins cholesterol (LDL-C) was then calculated
using Friedwald’s formula [13]. The very low-density
lipoproteins cholesterol (VLDL-C) was derived based
on the formula: VLDL-C = TG/2.2 [14]. The athero-
genic index of plasma (AIP) was calculated as the
logarithmically transformed ratio of molar concentra-
tions of TG to HDL-C [8].
Cardiovascular risk assessment and stratification
The Framingham risk score (FRS) was used to measure
the 10-year risk of cardiovascular events [15], and was
electronically calculated after entering the required pa-
rameters (age, sex, diabetes (yes/no), smoking (yes/no),
BP lowering medications (yes/no), SBP, TC and HDL-C)
on this web page: https://www.cvdriskchecksecure.com/
FraminghamRiskScore.aspx/. Actually, the FRS predicts
the 10-year risk of developing a coronary event (com-
posite of myocardial infarction and coronary death), and
is considered a standard and generally acceptable ap-
proach to risk prediction [16]. Participants were subse-
quently grouped into three classes, given they presented
a low risk (score < 10 %), a moderate risk (score 10–
20 %) or a high risk of CVD (score > 20 %) [15].
Statistical analysis
Data were coded, entered and analyzed using SPSS ver-
sion 20.0 (IBM SPSS Inc., Chicago, Illinois, USA). Re-
sults are presented as count (proportion) or mean ±
standard deviation (SD) where appropriate. The Student
t test or its nonparametric equivalent (Wilcoxon rank
sum) served for comparison of quantitative variables.
The Pearson correlation test was used to seek linear re-
lation between quantitative variables. Linear regression
analysis served to assess the impact of AIP on CVR by
both univariable and multivariable models (while adjust-
ing for confounders in a backward stepwise procedure).
A p value < 0.05 was used to characterize statistically sig-
nificant results.
Ethical considerations
Before starting the study, an authorization was obtained
from authorities of the Yaoundé University Teaching
Hospital, and an ethical clearance was delivered by the
Ethical Review Board of the Faculty of Medicine and
Biomedical Sciences of the University of Yaoundé I,
Cameroon. All the procedures used in the present study
were in keeping with the current revision of the Helsinki
Declaration. All participants were informed of the vari-
ous aspects of the study, and they were enrolled only
after providing a signed consent form.
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Results
We recruited 108 women, their ages varying between 45
and 80 years with a mean age of 56.4 ± 6.9 years
(Table 1). Sixteen women (14.8 %) were known diabetes
patients, and 37 (34.3 %) were known hypertensive. Five
women (4.6 %) were active smokers. Thirty six women
(33.3 %) regularly practiced a physical exercise (≥3 ses-
sions per week), and 49 (45.4 %) were regularly consum-
ing fruits and vegetables (i.e. at least thrice weekly).
The distribution of various clinical and biological vari-
ables measured is depicted by Table 1. AIP values ranged
from -0.40 to 0.85 with a mean of 0.21 ± 0.27. The distri-
bution of AIP was comparable between participants
aged ≤ 60 years and their counterparts (p = 0.188). Like-
wise, AIP values did not vary significantly with regard to
known diabetes (p = 0.511), known hypertension (p =
0.213), active smoking (p = 0.972), regular physical activ-
ity (p = 0.642), and regular consumption of fruits/vegeta-
bles (p = 0.154). AIP was positively and significantly
correlated with BMI (r = 0.234; p = 0.015), SBP (r = 0.350;
p < 0.001), DBP (r = 0.365; p < 0.001), FPG (r = 0.314; p =
0.001), uric acid (r = 0.374; p < 0.001), and TC (r = 0.374;
p < 0.001), but not with age (r = -0.104; p = 0.284;
Table 2).
The 10-year risk of cardiovascular events based on the
FRS varied between 1.2 % and >30 % with a mean of
13.4 ± 8.7 % (Table 1). Forty three participants (39.8 %)
had a low risk of CVD (<10 %), 39 women (36.1 %) had
a moderate risk (10–20 %), and 21 women (24.1 %)
had a high risk of CVD (>20 %). The AIP and the
FRS were significantly correlated with each other (r = 0.369,
p < 0.001; Table 2). Furthermore, there was a significant
relation between the FRS (as the dependent variable)
and the AIP in univariable linear regression analysis
(β = 11.94, 95 % confidence interval (CI): 6.15–17.72;
p < 0.001; R2 = 0.136).
In multivariable linear regression analysis after adjust-
ing for BMI, FPG, uric acid, DBP, and LDL-C, AIP did
not impact the risk of CVD anymore, even when BMI
and uric acid were removed from the model. The ad-
justed β coefficient for AIP in this last model (adjusted
for FPG, DBP and LDL-C) was 1.98 (95 % CI: -3.65–
7.61; p = 0.487). Of note, FPG (adjusted β = 4.95, 95 %
CI: 0.45–9.46; p = 0.032), DBP (adjusted β = 3.37, 95 %
CI: 2.31–4.42; p < 0.001) and LDL-C (adjusted β = 1.17,
95 % CI: 0.26–2.07; p = 0.012) were independent factors
impacting our women’s risk of CVD. These results are
extensively presented in another report [12].
Table 1 Distribution of clinical and biochemical parameters
Variable Minimum Maximum Mean ± SD Median (IQR)
Age 45 80 56.4 ± 6.9 56 (51.3–60)
BMI (kg/m2) 21.20 43.60 31.56 ± 5.27 31.6 (27.93–35.0)
Systolic BP (mmHg) 100.0 210.0 138.6 ± 23.6 140 (120–150)
Diastolic BP (mmHg) 60.0 120.0 80.2 ± 13.0 80 (70–90)
Uric acid (mg/l) 23.30 121.40 57.32 ± 18.19 53.9 (46.17–65.38)
FPG (g/l) 0.6 3.31 0.65 ± 0.30 0.79 (0.70–0.95)
TC (mmol/l) 2.72 10.96 5.92 ± 1.62 5.93 (4.75–6.83)
LDL-C (mmol/l) 0.57 9.17 4.11 ± 1.51 4.17 (3.15–4.89)
HDL-C (mmol/l) 0.54 2.28 1.25 ± 0.30 1.22 (1.04–1.42)
Triglycerides (mmol/l) 0.57 6.32 2.24 ± 1.22 2.01 (1.33–2.89)
VLDL-C (mmol/l) 0.26 2.87 1.02 ± 0.55 0.91 (0.61–1.32)
AIP -0.40 0.85 0.21 ± 0.27 0.20 (0.00–0.38)
FRS (%) 1.2 >30 13.37 ± 8.67 11.7 (6.3–18.51)
SD standard deviation, IQR interquartile range, BMI body mass index, BP blood pressure, FPG fasting plasma glucose, TC Total Cholesterol, LDL-C low-density
lipoproteins cholesterol, HDL-C high-density lipoproteins cholesterol, VLDL-C very low-density lipoproteins cholesterol, AIP atherogenic index of plasma,
FRS Framingham risk score
Table 2 Correlation between the atherogenic index of plasma
and other variables
Variable Coefficient p value
Age -0.104 0.284
BMI 0.234 0.015*
Systolic BP 0.350 <0.001*
Diastolic BP 0.365 <0.001*
FPG 0.314 0.001*
Uric acid 0.374 <0.001*
TC 0.374 <0.001*
FRS 0.369 <0.001*
BMI body mass index, BP blood pressure, FPG fasting plasma glucose, TC Total
Cholesterol, LDL-C low-density lipoproteins cholesterol, FRS Framingham risk score
*p value < 0.05
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Discussion
Results from this study showed that AIP and the risk
of CVD (assessed by the FRS) were significantly cor-
related with each other, though this correlation was
weak (r = 0.369). Furthermore, after adjusting for con-
founders, AIP seemed not to be an independent fac-
tor impacting the onset of CVD (p = 0.487).
We obtained higher AIP values (mean 0.21 ± 0.27)
than Nwagha et al. [17] in their group of Nigerian post-
menopausal women (mean 0.15 ± 0.35). Intriguingly, AIP
was not influenced by our women’s age, and thus the
duration of menopause, which concurs with results from
Nwagha et al. [17]. Indeed, although these authors found
that AIP levels significantly increased from before meno-
pause to 10 years post menopause and 20 years post
menopause (p < 0.0001), they did not show any signifi-
cant difference between 10 and 20 years post menopause
(p = 0.116) [17].
Likewise, we found no relation between AIP and
known history of diabetes, in contradiction with previ-
ous reports [10, 18]. In the same line, AIP was uninflu-
enced by regular physical exercise and regular
consumption of fruits/vegetables although these healthy
lifestyle interventions have been shown to reduce TG
levels and increase HDL-C titers [19–25]. As AIP is de-
rived from the ratio of TG to HDL-C, it is expected that
any action leading to a reduction in TG and/or an in-
crease in HDL-C would result in consequential reduc-
tion in AIP. These contradictory results we obtained
may be due to the lack of power or misreporting of in-
formation by our participants, as the reliability of data
collected relied solely on their declaration.
AIP was positively and significantly correlated with
BMI, SBP, DBP, FPG, uric acid, and TC which have been
cited as risks factors for CVD [3–6, 18, 26–29]. Some
authors have demonstrated for instance a close relation
between AIP and plasma uric acid [18, 26], especially in
women [26]. Therefore, we can guess that interventions
to lessen the above parameters would perhaps lead to
the diminution in AIP levels. As such, our postmeno-
pausal women should be encouraged to adopt healthy
lifestyles, as evidence has accumulated a beneficial effect
on these parameters [19–25, 30]. Besides, some pharma-
cological interventions (such as hormone replacement
therapy and vitamin D supplementation) could be con-
sidered, though most of them have yielded controversial
outcomes [31].
We also found a positive and significant correlation
between AIP and the risk of CVD. Based on our results,
we found that API values < 0.163 (45 women) could have
been associated with low, 0.163–0.273 (24 women) with
moderate, and above 0.273 (38 women) with high risk of
CVD. Mirroring our findings, Dobiásová M found that
AIP values increased with increasing cardiovascular risk,
and suggested that AIP values of -0.3 to 0.1 may be asso-
ciated with low, 0.1 to 0.24 with medium and above 0.24
with high risk of CVD [10]. However, the relation we ob-
served between AIP and the risk of CVD was weak,
given that only 14 % of the variation of the FRS could be
explained by the AIP (R2 = 0.136). Moreover, after
adjusting for BMI, FPG, uric acid, DBP, and LDL-C, the
association between AIP and the risk of CVD became
unlikely. These results do not corroborate those from
Dobiásová M where AIP, adjusted for age, BMI, waist
circumference, type 2 diabetes, blood pressure, smoking,
TG, TC, LDL-C, apolipoproteins B, HDL-C, and TC/
HDL-C, was the best independent driver of positive find-
ings at coronary angiography [10].
Our inability to find an independent influence of AIP
on the risk of CVD could perhaps find an explanation in
the lack of power, as the study was a cross-sectional one
with a relative small sample size. Another limitation of
this study could be the fact that, in the absence of
locally-developed tools to assess the cardiovascular risk,
we used the FRS which may lack to accurately assess the
cardiovascular risk in African populations as they may
present different patterns of CVD when compared with
developed countries [32]. Furthermore, enrolment of
participants in a hospital setting rather than in the com-
munity could have perhaps led to an overestimation of
their risk of CVD. Larger, community-based and well-
designed studies are therefore warranted in our milieu
to better investigate the relationship between AIP and
risk of CVD, especially among postmenopausal women.
Besides, other studies are required to further assess
whether AIP could be used as a valuable tool to predict
the risk of CVD.
Conclusion
This study conducted among 108 apparently healthy
Cameroonian postmenopausal women showed a signifi-
cant correlation between the atherogenic index of
plasma and BMI, SBP, DBP, FPG, uric acid, and TC, but
not with age, though these correlations were weak. How-
ever, AIP was not an independent factor impacting the
risk of CVD. More studies are needed to better elucidate
the interplay between AIP and risk of CVD in our
setting.
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